Advertisement
Mr. Gary Dreher, CEO, stated, "Significant improvements in AMDL's Chinaoperations combined with other recently announced events provide a financialplatform for the Company to improve its sales and earning profile during thesecond half of FY2008 and beyond, giving us greater confidence in AMDL'sfinancial performance in 2008. Accordingly, we anticipate AMDL will be to ina position to have our auditors remove the 'going concern' qualification afterthe end of the current fiscal year." The business improvement andopportunities referenced above include:
Advertisement
About Jade Pharmaceutical: Jade has access to the fastest growingpharmaceutical and consumer market in the world: China. AMDL, through itssubsidiaries, Jade currently manufactures large volume injection fluids,tablets and other related products, holding licenses for 133 products. It alsomanufactures 107 generic, over the counter and supplemental pharmaceuticalproducts under certified Chinese Good Manufacturing Practice (CGMP) standards.* FY2007 Sales of $15 million and, Gross Profits of $8.1 million; * In-licensed Human Papilloma Virus ("HPV") Diagnostic Test; * Signed LOI for the Purchase a China Based Pharmaceutical Distribution Company; * Signed an MOU for 200 Store Distribution Arrangements for theGoodnak Product Line;
SOURCE AMDL, Inc.
